Search filters
Update Reimbursement Fludrace®

Update Reimbursement Fludrace®

30/03/2023

The existing TBR for Fludrace® 62.50 micrograms has been expanded with the strength 31.25 micrograms. Because the health insurer...

Reimbursement Scheme Acecort®

Reimbursement Scheme Acecort®

27/02/2023

The health insurer fully reimburses Acecort® 1, 2 and 3 mg as off March 1, 2023. The reimbursement by TBR Nederland will therefore...

Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg for the treatment of HFpEF (LVEF >40%)

Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg for the treatment of HFpEF (LVEF >40%)

27/02/2023

The health insurer does not yet fully reimburse Forxiga® (dapagliflozin) 10 mg for the treatment of HFpEF (LVEF >40%). The...

Reimbursement Scheme Isturisa®

Reimbursement Scheme Isturisa®

16/06/2022

The health insurer does not fully reimburse Isturisa® 1mg, 5mg and 10mg. The producer of this medicine has therefore asked TBR...

Termination TerugBetaalRegeling Forxiga® - Chronic Kidney Disease

Termination TerugBetaalRegeling Forxiga® - Chronic Kidney Disease

28/04/2022

From May 1st 2022 onwards, Forxiga® (dapagliflozine) 10 mg for the treatment of chronic kidney disease (CKD) is fully reimbursed...

You are currently offline. Some pages or content may fail to load.